SGLT2i-associated erythrocytosis: closing the evidence gap.
作者信息
Chin-Yee Benjamin, Hsia Cyrus C
机构信息
Department of Pathology and Laboratory Medicine, London Health Sciences Centre, Western University, London, ON, Canada.
Division of Hematology, Department of Medicine, London Health Sciences Centre, Western University, London, ON, Canada.
出版信息
Blood Adv. 2025 Aug 26;9(16):4321-4322. doi: 10.1182/bloodadvances.2025016967.
Abstract
摘要
相似文献
1
SGLT2i-associated erythrocytosis: closing the evidence gap.
Blood Adv. 2025 Aug 26;9(16):4321-4322. doi: 10.1182/bloodadvances.2025016967.
2
Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes.
JAMA Netw Open. 2025 Jun 2;8(6):e2517086. doi: 10.1001/jamanetworkopen.2025.17086.
3
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study.
Cardiovasc Diabetol. 2025 Aug 1;24(1):314. doi: 10.1186/s12933-025-02871-w.
4
Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.
Cardiovasc Diabetol. 2022 Jun 3;21(1):92. doi: 10.1186/s12933-022-01520-w.
5
Dapagliflozin-Induced Erythrocytosis in Chronic Kidney Disease: A Rare Occurrence.
Cureus. 2024 Apr 23;16(4):e58823. doi: 10.7759/cureus.58823. eCollection 2024 Apr.
6
Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs.
Endocr Connect. 2025 Jun 21;14(6). doi: 10.1530/EC-24-0695. Print 2025 Jun 1.
7
Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport-2 inhibitor.
Clin Transplant. 2023 Aug;37(8):e15013. doi: 10.1111/ctr.15013. Epub 2023 May 11.
8
SGLT2 inhibition for patients with ADPKD - closing the evidence gap.
Nephrol Dial Transplant. 2025 Apr 8. doi: 10.1093/ndt/gfaf061.
9
Heterogeneous Cardiovascular Effects of SGLT2 Inhibitors in Type 2 Diabetes: A Causal Forest and Target Trial Emulation Study.
Eur J Prev Cardiol. 2025 Sep 1. doi: 10.1093/eurjpc/zwaf539.
10
Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users.
JAMA Surg. 2025 Apr 30. doi: 10.1001/jamasurg.2025.0940.
本文引用的文献
1
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females.
Blood Adv. 2025 Jul 8;9(13):3202-3212. doi: 10.1182/bloodadvances.2025016320.
2
Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review.
Blood Adv. 2025 May 13;9(9):2108-2118. doi: 10.1182/bloodadvances.2024015410.
3
Association Between SGLT2 Inhibitor Use and Change in Hemoglobin Among Adults with Diabetes: A Nationwide Cohort Study.
J Gen Intern Med. 2024 Aug;39(10):1945-1947. doi: 10.1007/s11606-024-08640-x. Epub 2024 Apr 9.
4
Sodium-glucose cotransporter-2 inhibitor-associated erythrocytosis: A retrospective cohort study.
J Intern Med. 2024 Jan;295(1):103-105. doi: 10.1111/joim.13722. Epub 2023 Sep 20.
5
Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport-2 inhibitor.
Clin Transplant. 2023 Aug;37(8):e15013. doi: 10.1111/ctr.15013. Epub 2023 May 11.
6
Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases.
Am J Hematol. 2023 Jul;98(7):E165-E167. doi: 10.1002/ajh.26933. Epub 2023 Apr 19.
7
Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review.
CMAJ Open. 2022 Nov 8;10(4):E988-E992. doi: 10.9778/cmajo.20210322. Print 2022 Oct-Dec.
8
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.
Blood. 2021 Dec 30;138(26):2886-2889. doi: 10.1182/blood.2021013996.
Zotero 插件